Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
10(53%)
Results Posted
100%(5 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_1
4
21%
Ph phase_3
2
11%
Ph phase_2
11
58%
Ph phase_4
2
11%

Phase Distribution

4

Early Stage

11

Mid Stage

4

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
11(57.9%)
Phase 3Large-scale testing
2(10.5%)
Phase 4Post-market surveillance
2(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

10

trials recruiting

Total Trials

19

all time

Status Distribution
Active(12)
Completed(5)
Terminated(2)

Detailed Status

Recruiting8
Completed5
Not yet recruiting2
Active, not recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
10
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (21.1%)
Phase 211 (57.9%)
Phase 32 (10.5%)
Phase 42 (10.5%)

Trials by Status

completed526%
not_yet_recruiting211%
recruiting842%
withdrawn15%
active_not_recruiting211%
terminated15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07116031Phase 2

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

Recruiting
NCT06046248Phase 2

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Recruiting
NCT06476132Phase 2

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Recruiting
NCT07006506Phase 2

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Recruiting
NCT06082037Phase 3

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Recruiting
NCT04643002Phase 1

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
NCT07484113Phase 1

IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

Not Yet Recruiting
NCT07135973Phase 4

A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Not Yet Recruiting
NCT05996627Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting
NCT05567406Phase 2

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Withdrawn
NCT05922761Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting
NCT06143891Phase 3

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Active Not Recruiting
NCT05806567Phase 1

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Completed
NCT06616415Phase 4

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

Active Not Recruiting
NCT04680975Phase 2

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis

Terminated
NCT02688647Phase 2

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Completed
NCT03530995Phase 1

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Completed
NCT02106195Phase 2

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Completed
NCT02852967Phase 2

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19